Summary
Global Markets Direct’s, ‘Cataract - Pipeline Review, H1 2016’, provides an overview of the Cataract pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cataract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cataract and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cataract
- The report reviews pipeline therapeutics for Cataract by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cataract therapeutics and enlists all their major and minor projects
- The report assesses Cataract therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cataract
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cataract
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
EyeGate Pharmaceuticals, Inc.
Genisphere Inc.
InSite Vision Incorporated
Laboratorios Sophia S.A. de C.V.
Omeros Corporation
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cataract Overview 6
Therapeutics Development 7
Pipeline Products for Cataract - Overview 7
Pipeline Products for Cataract - Comparative Analysis 8
Cataract - Therapeutics under Development by Companies 9
Cataract - Therapeutics under Investigation by Universities/Institutes 10
Cataract - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Cataract - Products under Development by Companies 13
Cataract - Products under Investigation by Universities/Institutes 14
Cataract - Companies Involved in Therapeutics Development 15
EyeGate Pharmaceuticals, Inc. 15
Genisphere Inc. 16
InSite Vision Incorporated 17
Laboratorios Sophia S.A. de C.V. 18
Omeros Corporation 19
Cataract - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(bromfenac sodium + dexamethasone acetate) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexamethasone acetate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GL-249 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
lanosterol - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PRO-155 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Antagonize GPR161 for Oncology, Ophthalmology and Central Nervous System Disorders - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Cataract - Recent Pipeline Updates 39
Cataract - Dormant Projects 40
Cataract - Discontinued Products 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43
List of Tables
Number of Products under Development for Cataract, H1 2016 7
Number of Products under Development for Cataract - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Cataract - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016 15
Cataract - Pipeline by Genisphere Inc., H1 2016 16
Cataract - Pipeline by InSite Vision Incorporated, H1 2016 17
Cataract - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2016 18
Cataract - Pipeline by Omeros Corporation, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Assessment by Combination Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Cataract Therapeutics - Recent Pipeline Updates, H1 2016 39
Cataract - Dormant Projects, H1 2016 40
Cataract - Discontinued Products, H1 2016 41
List of Figures
Number of Products under Development for Cataract, H1 2016 7
Number of Products under Development for Cataract - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 22
Number of Products by Stage and Targets, H1 2016 22
Number of Products by Mechanism of Actions, H1 2016 24
Number of Products by Stage and Mechanism of Actions, H1 2016 24
Number of Products by Routes of Administration, H1 2016 26
Number of Products by Stage and Routes of Administration, H1 2016 26
Number of Products by Top 10 Molecule Types, H1 2016 28
Number of Products by Stage and Top 10 Molecule Types, H1 2016 28
